<DOC>
	<DOCNO>NCT01673672</DOCNO>
	<brief_summary>The purpose study assess therapeutic potential safety/tolerability study drug ( CYT003 ) 3 dose level versus placebo patient persistent moderate severe allergic asthma sufficiently control current standard controller therapy . Altogether 360 patient randomize 4 treatment group include . The study compare three dose strength placebo . Each patient receive 7 injection study drug undistinguishable placebo . Key outcome measure patient report parameter asthma .</brief_summary>
	<brief_title>CYT003-QbG10 , TLR9-agonist , Treatment Uncontrolled Moderate Severe Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Able willing provide write informed consent Able willing complete protocol requirement Between 18 65 year age Presence persistent asthma least 6 month accord GINA 2011 guideline step 3 4 treatment stable controller therapy least 4 week , symptom sufficiently control medium high dos inhale corticosteroid ( ICS ) ( &gt; 250 ≤1000 µg/day fluticasone equivalent ) combination without long act beta agonist ( LABA ) , insufficient control base asthma control questionnaire ( ACQ ) score ≥1.5 point . Use stable dos controller therapy accord GINA step 3 4 ( leukotriene modifier , sustain release theophylline ) also acceptable , NOT treatment anti immunoglobulin E ( IgE ) antibody within past 6 month Stable insufficiently control baseline condition document ACQ ≥1.5 screen baseline visit . Positive skin prick test ( SPT ) radioallergosorbent test ( RAST ) least 1 aeroallergen screen period Forced expiratory volume one second ( FEV1 ) ≥40 ≤90 % predict value Reversibility airway obstruction demonstrate : FEV1 improvement &gt; 12 % , By ≥200 mL inhale β2agonist ( 400 µg salbutamol equivalent ) . If subject meet reversibility criterion screen visit , reversibility may retested prior runin long test perform least 5 day prior begin runin phase Failure meet least 80 % compliance completion asthma symptom medication diary baseline visit , initial instruction screen visit necessary additional training 2weeks runin visit . . An additional maximum 2weeks training period may add patient . Treatment hospitalization asthma exacerbation within past 2 month . Current use use systemic corticosteroid within past 2 month . Current smoker . Exsmokers smoke history &gt; 10 pack year ( 1 package per day 10 year ) . Pregnancy female planning become pregnant study period . Ongoing plan specific immunotherapy ( SIT ) whole study period SIT complete within last 3 year . Treatment IgE antibody ( Xolair® ) within past 6 month . Use investigational unapproved drug within 30 day within 5 halflives investigational drug , whichever longer , plan use whole study period . Use investigational biologics within last 6 month . Previous participation clinical study virus like particle ( VLP ) Qbbased vaccine . Possible dependency patient sponsor and/or investigator . Women child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>